Devices · Resonance Health Analysis Services Pty Ltd
HepaFat-AI
Resonance Health Analysis Services Pty Ltd is listed for HepaFat-AI (K201039). The FDA list gives December 7, 2020 as the date of the final decision. The lead panel is Radiology, and the database link on the FDA list is the 510(k) pathway. The primary product code on the FDA list is LNH. openFDA did not return a classification record for that code in this copy of the data. openFDA records this submission’s decision description as “Substantially Equivalent.” This paragraph is assembled only from those public fields. It is not an FDA review, not a determination of safety or effectiveness, and not medical advice. Official record: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K201039
- Date of final decision
- December 7, 2020
- Company on the FDA list
- Resonance Health Analysis Services Pty Ltd
- Lead panel
- Radiology
- Primary product code
- LNH
- openFDA device name for the code
- System, Nuclear Magnetic Resonance Imaging
- Device class
- 2
- Regulation number
- 892.1000
- openFDA decision description
- Substantially Equivalent
- openFDA decision code
- SESE
- Statement or summary label
- Summary